Quick Dispatch:
Your tirzepatide cardiovascular outcomes study Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cardiovascular outcomes study Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity ships.
Need Help?
Questions about tirzepatide cardiovascular outcomes study Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cardiovascular outcomes study Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity in your area.
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
24.57
Possible mechanisms of Tirzepatide's cardiovascular benefits
22.27
Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism
25.20
CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 8 RANDOMIZED CLINICAL TRIALS
20.18
SUMMIT: Tirzepatide Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity
21.71
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology
29.87
Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky
24.34
